Literature DB >> 178409

Climbing fiver activation and 3', 5'-cyclic guanosine monophosphate (cGMP) content in cortex and deep nuclei of cerebellum.

G Biggio, A Guidotti.   

Abstract

Harmaline (28 mumoles/kg u.v.), cold exposure (4C) or isoniazid (2.2 mmoles/kg s.c.) increased the cGMP content in rat cerebellar cortex several fold. Isoniazid but not harmaline or cold exposure increased cGMP in the deep cerebellar nuclei (nuclei interpositus, vestibularis and fastigius) and striatum. In rats treated with the nicotinamide antagonist 3-acetylpyridine (3-AP) (0.66 mumoles/kg i.p. 4 days before) the tremorogenic effect of harmaline and the increase of cerebellar cortex cGMP produced by this alkaloid was abated. Similarly the increase of cGMP following exposure to cold was reduced. In contrast isoniazid and glutamate (10 mumoles intraventricularly) increased cGMP to the same extent in control and 3-AP treated rats. Since 3-AP produces in rat a massive degeneration of the inferior olivary nucleus and of the climbing fibers but leaves intact all the other cerebellar elements, these experiments suggest that an increase of cGMP content in postsynaptic cerebellar elements (presumable Purkinje cells) may be an expression of an increased release of an excitatory transmitter from either the climbing fivers or the parallel fibers.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 178409     DOI: 10.1016/0006-8993(76)90233-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

Review 1.  NO as a multimodal transmitter in the brain: discovery and current status.

Authors:  John Garthwaite
Journal:  Br J Pharmacol       Date:  2018-12-05       Impact factor: 8.739

2.  Voltage-sensitive calcium channels regulate guanosine 3',5'-cyclic monophosphate levels in neuroblastoma cells.

Authors:  R E Study; X O Breakefield; T Bartfai; P Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

3.  Kainic acid-induced lesion of dopaminergic target cells in the striatum: consequences on the dynamics of cerebellar cGMP.

Authors:  G Biggio; M G Corda; M Casu; G L Gessa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-08       Impact factor: 3.000

Review 4.  Histochemistry of nucleotidyl cyclases and cyclic nucleotide phosphodiesterases.

Authors:  G Poeggel; H Luppa
Journal:  Histochem J       Date:  1988-05

Review 5.  A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

6.  Effect of chlormethiazole, dizocilpine and pentobarbital on harmaline-induced increase of cerebellar cyclic GMP and tremor.

Authors:  A J Cross; A Misra; A Sandilands; M J Taylor; A R Green
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Excitatory amino acid recognition sites coupled with inositol phospholipid metabolism: developmental changes and interaction with alpha 1-adrenoceptors.

Authors:  F Nicoletti; M J Iadarola; J T Wroblewski; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Stimulation of rat cerebellar guanosine 3',5'-cyclic monophosphate (cyclic GMP) levels: effects of amino acid antagonists.

Authors:  G A Foster; P J Roberts
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

9.  Exaggerated norepinephrine-stimulated accumulation of cyclic AMP in vitro in cerebellar slices from pcd mutant mice following Purkinje cell loss.

Authors:  M J Schmidt; B Ghetti
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

10.  Mechanisms by which diazepam, muscimol, and other drugs change the content of cGMP in cerebellar cortex.

Authors:  G Biggio; B B Brodie; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.